Glucose and Hormonal Regulation: Acute and Complex Alterations

Comprehensive vocabulary flashcards covering key concepts, diagnostic criteria, clinical features, and pharmacotherapy for disorders of glucose regulation (DKA, HHS, aging) and hormonal regulation (DI, SIADH, Thyroid Storm, Myxedema Coma, aging).

Clinical Manifestations of Diabetes Mellitus

The hallmark signs of insulin insufficiency and hyperglycemia, encompassing the classic 3 Ps (polyuria, polydipsia, and polyphagia), along with sudden weight loss, fatigue, poor wound healing, blurry vision, vaginal infections, sexual dysfunction, and numbness or tingling in the hands and feet.

Hemoconcentration

A decrease in the fluid content of the plasma due to dehydration from osmotic diuresis, which causes blood cells and circulating solutes to become abnormally packed together and concentrated.

Hyperviscosity

An abnormal thickening of the blood into a viscous, syrup-like consistency caused by profound fluid loss and hyperglycemia, which impairs microvascular circulation and forces the heart to work harder to perfuse tissue beds.

Ketogenesis

The hepatic metabolic pathway triggered by profound cellular insulin deficiency, wherein the liver breaks down stored fats and fatty acids into acidic ketone bodies (ketones), precipitating metabolic acidosis.

Diabetic Ketoacidosis (DKA)

A life-threatening acute metabolic crisis characterized by profound insulin deficiency, serum blood glucose $> 250\,\text{mg/dL}$, arterial $\text{pH} < 7.30$, serum bicarbonate $< 18\,\text{mEq/L}$, positive serum and urine ketones, severe dehydration, and an elevated anion gap.

Kussmaul Respirations

A rapid, deep breathing pattern that represents respiratory compensation in diabetic ketoacidosis, functioning to blow off excess carbon dioxide ($\text{CO}_2$) and mitigate metabolic acidosis.

Anion Gap

A calculated diagnostic laboratory measurement reflecting electrolyte balance; a value $> 12$ signifies an excess of unmeasured organic acids, confirming the presence of high anion gap metabolic acidosis in DKA.

Markers for Resolution of DKA

A specific triad of clinical laboratory endpoints confirming stabilization: blood glucose $< 200\,\text{mg/dL}$, serum bicarbonate $> 18\,\text{mEq/L}$, and venous or arterial $\text{pH} > 7.3$.

Intravenous Regular Insulin Infusion Protocol for DKA

The primary pharmacological replacement regimen in DKA consisting of an initial IV bolus of $0.1\,\text{unit/kg}$ of Regular insulin followed by a continuous infusion of $0.1\,\text{unit/kg/hr}$, adjusted to achieve an hourly blood glucose reduction of $50\text{--}70\,\text{mg/dL}$.

Hyperglycemic Hyperosmolar State (HHS)

A severe acute hyperglycemic complication most commonly seen in older adults with Type 2 diabetes, distinguished by profound dehydration, serum glucose $\ge 600\,\text{mg/dL}$ (frequently $\ge 1000\,\text{mg/dL}$), serum osmolality $> 320\,\text{mOsm/kg}$, arterial $\text{pH} > 7.3$, bicarbonate $> 18\,\text{mEq/L}$, neurological decline, and the absence of significant ketosis.

Oliguria

A state of abnormally diminished urine output defined quantitatively as $< 30\,\text{mL/hr}$ or $< 400\,\text{mL/day}$, produced by severe hypovolemia and compromised renal perfusion during crises such as advanced HHS.

Age-Related Alterations in Glucose Regulation

Senescent metabolic alterations including increased visceral adipose tissue, loss of lean muscle mass (the primary site of glucose uptake), and diminished pancreatic insulin secretion, predisposing older adults to undertreated Type 2 diabetes and end-stage renal disease.

Diabetes Insipidus (DI)

A neuroendocrine condition caused by a deficiency of or cellular insensitivity to antidiuretic hormone (ADH/vasopressin), presenting with massive dilute polyuria (up to $20\,\text{L/day}$), extreme thirst, urine specific gravity $< 1.005$, urine osmolality $< 300\,\text{mOsm/L}$, and hypernatremia ($> 145\,\text{mEq/L}$).

Central Diabetes Insipidus

Neurogenic DI caused by insufficient synthesis or release of antidiuretic hormone (ADH) from the hypothalamus or posterior pituitary gland, frequently secondary to head trauma, pituitary surgery, or craniotomy.

Nephrogenic Diabetes Insipidus

A disorder in which the hypothalamus and pituitary secrete adequate antidiuretic hormone (ADH), but the renal collecting tubules fail to respond, leading to uninhibited free water excretion.

Dipsogenic Diabetes Insipidus

A rare variant of diabetes insipidus resulting from a primary defect in thirst regulation or compulsive polydipsia, characterized by extreme water consumption exceeding $5\,\text{L/day}$.

Water Deprivation Test

A diagnostic protocol where fluids are withheld for $8\,\text{hours}$ before administering exogenous vasopressin; a reduction in urine output and concentration of urine confirms Central DI, while persistent dilute diuresis identifies Nephrogenic DI.

Desmopressin (DDAVP)

A synthetic analog of antidiuretic hormone and the pharmacologic drug of choice for central diabetes insipidus, preferred because it provides selective antidiuretic action with negligible impact on systemic arterial blood pressure.

Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

An endocrine disorder marked by autonomous, excessive release of antidiuretic hormone (ADH) independent of serum osmolality, resulting in pathological renal water reabsorption, low urinary output, elevated urine osmolality ($> 100\,\text{mOsm/L}$), and dilutional hyponatremia.

Dilutional Hyponatremia

A state of decreased serum sodium concentration ($< 125\,\text{mEq/L}$) produced by excess fluid retention rather than total body sodium loss; critical reductions ($< 120\,\text{mEq/L}$) induce cerebral edema, lethargy, decreased reflexes, seizures, and coma.

Vaptans (Conivaptan and Tolvaptan)

A class of vasopressin receptor antagonists prescribed in the collaborative management of SIADH to block renal V2 receptors, promoting aquaresis (free water excretion without electrolyte excretion) to correct euvolemic hyponatremia.

Diabetes Insipidus vs. SIADH

Two opposing antidiuretic hormone disorders: DI is characterized by low ADH, high urinary output, hypernatremia, and hypovolemic dehydration, whereas SIADH is characterized by high ADH, low urinary output, hyponatremia, and hypervolemic fluid retention.

Thyroid Storm (Thyroid Crisis)

A rare, life-threatening hypermetabolic medical emergency caused by excessive circulating levels of free $\text{T}_3$ and $\text{T}_4$, characterized clinically by hyperthermia, extreme tachycardia, tachyarrhythmias (such as atrial fibrillation), systolic hypertension, agitation, delirium, and gastrointestinal hyperactivity.

Goiter

An abnormal macroscopic enlargement of the thyroid gland in the anterior neck that can compress the trachea and esophagus, causing dyspnea and dysphagia in patients with severe thyroid disorders.

Propylthiouracil (PTU)

An antithyroid thionamide drug used in the treatment of thyroid storm to inhibit thyroid hormone synthesis; requires close monitoring for immunosuppression and hepatotoxicity (manifesting as jaundice, scleral icterus, or tea-colored urine).

Methimazole (Tapazole)

An oral antithyroid agent that blocks thyroid hormone production; notable for being a potent teratogen, requiring immediate discontinuation and provider notification if pregnancy occurs.

Myxedema Coma

An extreme, life-threatening decompensation of hypothyroidism characterized by severe lack of thyroid hormone ($\text{TH}$), marked hypothermia, hypoventilation leading to respiratory acidosis, severe bradycardia, hypotension, and generalized depression of all bodily metabolic processes.

Intravenous Levothyroxine (Synthroid)

The emergency synthetic thyroid hormone replacement administered intravenously as a loading bolus to treat myxedema coma; requires cautious titration to avoid triggering myocardial ischemia, angina, or fatal dysrhythmias.

Age-Related Alterations in Hormonal Regulation

The gradual decline in endocrine function associated with advanced age, characterized by decreased thyroid hormone secretion and an insidious onset of hypothyroidism, requiring a 'start low and go slow' pharmacologic dosing approach.